Archive for category: Portfolio Companies

Northridge, CA and Cambridge, United Kingdom, 7 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for […]

Northridge, CA and Cambridge, United Kingdom, 5 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®. The IDE […]

Link here. 30 September 2015. Highlights: BARDA contract commits initial USD16.9m to support Avita’s FDA approval trial for treatment of thermal burn injuries and procure 5000-plus ReCell® devices. Contract also establishes a strategic, Avita-managed stockpile for ReCell® devices to supply nationally. A further potential to receive USD37M in contract options to support additional clinical trials and […]

DUBLIN, Ireland, Sept. 29, 2015 (GLOBE NEWSWIRE). Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced receipt of US$3.2 million in cash under the Australian Federal Government’s Research and Development (R&D) Tax Incentive program. This program provides a 45 percent refundable tax offset for qualifying R&D in Australia, where Nexvet conducts its drug discovery […]

DUBLIN, Ireland, Sept. 16, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced it has secured a dedicated biologics manufacturing facility in Tullamore, Ireland. The transaction is supported the Irish Government’s Department of Jobs, Enterprise & Innovation through IDA Ireland, their foreign investment agency. BioNua Limited, a wholly-owned subsidiary […]